Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beigene ADS Representing Ord Shs ONC

Healthcare Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the... see more

Recent & Breaking News (NDAQ:ONC)

BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)

GlobeNewswire June 14, 2019

BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)

GlobeNewswire June 12, 2019

BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

GlobeNewswire June 5, 2019

BeiGene Chief Executive Officer John V. Oyler Elected to BIO Board of Directors

GlobeNewswire June 4, 2019

BeiGene Announces Preliminary Phase 2 Results of Tislelizumab in Chinese Patients with Nasopharyngeal Cancer at the 2019 ASCO Annual Meeting

GlobeNewswire June 1, 2019

BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer

GlobeNewswire May 30, 2019

BeiGene Announces Acceptance of a Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma

GlobeNewswire May 30, 2019

BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association

GlobeNewswire May 16, 2019

BeiGene Reports First Quarter 2019 Financial Results

GlobeNewswire May 9, 2019

BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy

GlobeNewswire April 9, 2019

BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting

GlobeNewswire April 1, 2019

Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics

GlobeNewswire March 6, 2019

BeiGene to Present at Upcoming Investor Conferences

GlobeNewswire March 4, 2019

BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire February 27, 2019

BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference

GlobeNewswire February 22, 2019

BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma

GlobeNewswire February 19, 2019

BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong

GlobeNewswire February 13, 2019

BeiGene to Present at the Guggenheim Healthcare Talks Idea Forum – Oncology Day

GlobeNewswire February 7, 2019

BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma

GlobeNewswire January 14, 2019

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire January 3, 2019